Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination

被引：77

作者：

Verheust, Celine ^{[1
]}

Goossens, Martine ^{[1
]}

Pauwels, Katia ^{[1
]}

Breyer, Didier ^{[1
]}

机构：

[1] Sci Inst Publ Hlth, Biosafety & Biotechnol Unit, B-1050 Brussels, Belgium

来源：

VACCINE | 2012年 / 30卷 / 16期

关键词：

Biosafety; MVA-based recombinant vectors; Risk assessment; GMO-based vaccines; Clinical trials; Environmental safety; COLORECTAL-CANCER PATIENTS; T-CELL RESPONSES; TUBERCULOSIS VACCINE; HOST-RANGE; PHASE-II; MALARIA VACCINATION; RECOMBINANT VIRUSES; FALCIPARUM-MALARIA; IMMUNE-RESPONSES; GENOMIC SEQUENCE;

D O I：

10.1016/j.vaccine.2012.02.016

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The modified vaccinia virus Ankara (MVA) strain is a highly attenuated strain of vaccinia virus that has been demonstrated to be safe for humans. MVA is widely considered as the vaccinia virus strain of choice for clinical investigation because of its high safety profile. It also represents an excellent candidate for use as vector system in recombinant vaccine development for gene delivery or vaccination against infectious diseases or tumours, even in immunocompromised individuals. The use of MVA and recombinant MVA vectors must comply with various regulatory requirements, particularly relating to the assessment of potential risks for human health and the environment. The purpose of the present paper is to highlight some biological characteristics of MVA and MVA-based recombinant vectors and to discuss these from a biosafety point of view in the context of the European regulatory framework for genetically modified organisms with emphasis on the assessment of potential risks associated with environmental release. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：2623 / 2632

页数：10

共 50 条

[1] Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
Goossens, Martine
Pauwels, Katia
Willemarck, Nicolas
Breyer, Didier
CURRENT GENE THERAPY, 2013, 13 (06) : 413 - 420
[2] General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination
Baldo, Aline
van den Akker, Eric
Bergmans, Hans E.
Lim, Filip
Pauwels, Katia
CURRENT GENE THERAPY, 2013, 13 (06) : 385 - 394
[3] Biosafety of Viral Vectors Commonly Used in Gene Therapy and Vaccination
Herman, Philippe
CURRENT GENE THERAPY, 2013, 13 (06) : 383 - 384
[4] Modified Vaccinia Virus Ankara (MVA) based Vaccines - Immunostimulatory and Protective Capacity
Lehmann, Michael H.
Kremer, Melanie
Suezer, Yasemin
Sutter, Gerd
CHALLENGE OF HIGHLY PATHOGENIC MICROORGANISMS: MECHANISMS OF VIRULENCE AND NOVEL MEDICAL COUNTERMEASURES, 2010, : 245 - +
[5] Modified vaccinia virus Ankara as a vector for suicide gene therapy
P Erbs
A Findeli
J Kintz
P Cordier
C Hoffmann
M Geist
J-M Balloul
Cancer Gene Therapy, 2008, 15 : 18 - 28
[6] Modified vaccinia virus Ankara as a vector for suicide gene therapy
Erbs, P.
Findeli, A.
Kintz, J.
Cordier, P.
Hoffmann, C.
Geist, M.
Balloul, J-M
CANCER GENE THERAPY, 2008, 15 (01) : 18 - 28
[7] Heat-inactivated modified vaccinia virus Ankara (MVA) as vaccine adjuvant
Yang, Ning
Shuman, Stewart
Merghoub, Taha
Wolchok, Jedd
Deng, Liang
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[8] Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
Stittelaar, KJ
Kuiken, T
de Swart, RL
van Amerongen, G
Vos, HW
Niesters, HGM
van Schalkwijk, P
van der Kwast, T
Wyatt, LS
Moss, B
Osterhaus, ADME
VACCINE, 2001, 19 (27) : 3700 - 3709
[9] Vectors for recombinational cloning and gene expression in mammalian cells using modified vaccinia virus Ankara
Pradeau-Aubreton, Karine
Ruff, Marc
Gamier, Jean-Marie
Schultz, Patrick
Drillien, Robert
ANALYTICAL BIOCHEMISTRY, 2010, 404 (01) : 103 - 105
[10] Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination
Breathnach, CC
Rudersdorf, R
Lunn, DP
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2004, 98 (3-4) : 127 - 136

← 1 2 3 4 5 →